JP2012520249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520249A5 JP2012520249A5 JP2011553352A JP2011553352A JP2012520249A5 JP 2012520249 A5 JP2012520249 A5 JP 2012520249A5 JP 2011553352 A JP2011553352 A JP 2011553352A JP 2011553352 A JP2011553352 A JP 2011553352A JP 2012520249 A5 JP2012520249 A5 JP 2012520249A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- urinary incontinence
- epilepsy
- mania
- migraine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims description 10
- 206010046543 Urinary incontinence Diseases 0.000 claims description 9
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010026749 Mania Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- -1 3-chloro-2-hydroxypropylthio Chemical group 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- CKWKREFECQVBBZ-UHFFFAOYSA-N 2-sulfanylidene-1h-quinoline-3-carboxamide Chemical class C1=CC=C2N=C(S)C(C(=O)N)=CC2=C1 CKWKREFECQVBBZ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 1
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 description 1
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
Description
さらに、ＫＣＮＱ２／３Ｋ＋チャンネルは、多数の他の疾患、例えば偏頭痛（米国特許第２００２／０１２８２７７号明細書）、認識疾患（Ｇｒｉｂｋｏｆｆ著， Ｅｘｐｅｒｔ Ｏｐｉｎ Ｔｈｅｒ Ｔａｒｇｅｔｓ ２００３； ７（６）： ７３７−７４８）、不安状態（Ｋｏｒｓｇａａｒｄ ｅｔ ａｌ．著， Ｊ Ｐｈａｒｍａｃｏｌ Ｅｘｐ Ｔｈｅｒ． ２００５， １４（１）： ２８２−９２）、てんかん（Ｗｉｃｋｅｎｄｅｎ ｅｔ ａｌ．著， Ｅｘｐｅｒｔ Ｏｐｉｎ Ｔｈｅｒ Ｐａｔ ２００４， １４（４）： ４５７−４６９； Ｇｒｉｂｋｏｆｆ著， Ｅｘｐｅｒｔ Ｏｐｉｎ Ｔｈｅｒ Ｔａｒｇｅｔｓ ２００８， １２（５）： ５６５−８１； Ｍｉｃｅｌｉ ｅｔ ａｌ．著， Ｃｕｒｒ Ｏｐｉｎ Ｐｈａｒｍａｃｏｌ ２００８， ８（１）： ６５−７４）、尿失禁（Ｓｔｒｅｎｇ ｅｔ ａｌ．著， Ｊ Ｕｒｏｌ ２００４；１７２： ２０５４−２０５８）、依存症（Ｈａｎｓｅｎ ｅｔ ａｌ．著， Ｅｕｒ Ｊ Ｐｈａｒｍａｃｏｌ ２００７， ５７０（１−３）： ７７−８８）、躁病／双極性障害（Ｄｅｎｃｋｅｒ ｅｔ ａｌ．著， Ｅｐｉｌｅｐｓｙ Ｂｅｈａｖ ２００８， １２（１）： ４９−５３）、筋失調に関連する運動障害（Ｒｉｃｈｔｅｒ ｅｔ ａｌ．著， Ｂｒ Ｊ Ｐｈａｒｍａｃｏｌ ２００６， １４９（６）： ７４７−５３）の治療のための適当な対象である。
有利に、本発明による医薬は、痛み、有利に急性痛、慢性痛、神経障害性痛、筋肉性痛及び炎症性痛からなる群から選択される痛み；てんかん、尿失禁、不安状態、依存症、躁病、双極性障害、偏頭痛、認識疾患、筋失調と関連する運動障害及び／又は尿失禁からなる群から選択される１種又は数種の疾患の治療のために適している。
痛み、有利に急性痛、慢性痛、神経障害性痛、筋肉性痛及び炎症性痛から選択される痛み；てんかん、尿失禁、不安状態、依存症、躁病、双極性障害、偏頭痛、認識障害、筋失調と関連する運動障害及び／又は尿失禁を治療するための医薬を製造するための、少なくとも１種の本発明による置換された２−メルカプトキノリン−３−カルボキサミド並びに場合により１種若しくは数種の製剤学的に許容された助剤の使用が有利である。
本発明の他の主題は、痛み、有利に急性痛、慢性痛、神経障害性痛、筋肉性痛及び炎症性痛から選択される痛み；てんかん、尿失禁、不安状態、依存症、躁病、双極性障害、偏頭痛、認識障害、筋失調と関連する運動障害及び／又は尿失禁を治療するための、少なくとも１種の本発明による置換された２−メルカプトキノリン−３−カルボキサミド並びに場合により１種若しくは数種の製剤学的に許容された助剤である。
Claims (1)
- 痛み、てんかん、尿失禁、不安状態、依存症、躁病、双極性障害、偏頭痛、認識障害、筋失調と関連する運動障害及び／又は尿失禁の治療のための医薬を製造するための、それぞれ個々の立体異性体又はその混合物、遊離化合物及び／又はその生理学的に許容される塩の形態での請求項１から１３のいずれか一項に記載の少なくとも１種の置換されたカルボキサミド又はＮ−ベンジル−２−（３−クロロ−２−ヒドロキシプロピルチオ）−４−（２，４−ジクロロフェニル）キノリン−３−カルボキサミドの化合物の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09003597 | 2009-03-12 | ||
| EP09003597.3 | 2009-03-12 | ||
| PCT/EP2010/001509 WO2010102811A1 (de) | 2009-03-12 | 2010-03-11 | Substituierte 2-mercaptochinolin-3-carboxamide als kcnq2/3 modulatoren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520249A JP2012520249A (ja) | 2012-09-06 |
| JP2012520249A5 true JP2012520249A5 (ja) | 2014-10-16 |
| JP5727946B2 JP5727946B2 (ja) | 2015-06-03 |
Family
ID=40671387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553352A Expired - Fee Related JP5727946B2 (ja) | 2009-03-12 | 2010-03-11 | Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプトキノリン−３−カルボキサミド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20100234372A1 (ja) |
| EP (1) | EP2406229A1 (ja) |
| JP (1) | JP5727946B2 (ja) |
| KR (1) | KR20110132590A (ja) |
| CN (1) | CN102348692A (ja) |
| AR (1) | AR075824A1 (ja) |
| AU (1) | AU2010223513B2 (ja) |
| BR (1) | BRPI1008939A2 (ja) |
| CA (1) | CA2755004A1 (ja) |
| CL (1) | CL2011002209A1 (ja) |
| CO (1) | CO6410292A2 (ja) |
| EC (1) | ECSP11011348A (ja) |
| IL (1) | IL214945A0 (ja) |
| MX (1) | MX2011009369A (ja) |
| NZ (1) | NZ595625A (ja) |
| PE (1) | PE20120790A1 (ja) |
| RU (1) | RU2011141188A (ja) |
| TW (1) | TWI461197B (ja) |
| WO (1) | WO2010102811A1 (ja) |
| ZA (1) | ZA201107444B (ja) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3178067B2 (ja) | 1991-02-26 | 2001-06-18 | ぺんてる株式会社 | スズ−ニッケル二元合金電気めっき液組成物 |
| TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| WO2010102778A2 (de) * | 2009-03-10 | 2010-09-16 | Grünenthal GmbH | Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren |
| TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| PE20140214A1 (es) | 2010-08-27 | 2014-02-19 | Gruenenthal Chemie | 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores kcnq2/3 |
| BR112013004562A2 (pt) | 2010-08-27 | 2016-09-06 | Gruenenthal Gmbh | 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3 |
| AU2011297937B2 (en) | 2010-09-01 | 2015-10-01 | Grunenthal Gmbh | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators |
| MX2015004511A (es) | 2012-10-11 | 2015-07-06 | Grünenthal GmbH | Tratamiento y/o profilaxis de enfermedades y/o trastornos provocados por tspo. |
| CA2892652A1 (en) | 2012-11-28 | 2014-06-05 | Grunenthal Gmbh | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |
| MX2015006689A (es) | 2012-11-28 | 2015-08-20 | Grünenthal GmbH | Carboxamidas especificas como moduladores de kcnq2/3. |
| US9248122B2 (en) | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
| BR112015017997B1 (pt) * | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas de quinolina e quinoxalina como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| US9096549B2 (en) | 2013-02-01 | 2015-08-04 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN108530458A (zh) | 2013-11-01 | 2018-09-14 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
| PH12015000236B1 (en) * | 2015-07-06 | 2024-01-10 | Samsung Electronics Co Ltd | Electronic device for providing a calibrated keyboard configuration |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| WO2018110669A1 (en) | 2016-12-15 | 2018-06-21 | Ono Pharmaceutical Co., Ltd. | Activator of trek (twik related k+ channels) channels |
| DE102018212006B3 (de) | 2018-07-18 | 2019-10-31 | Universität Greifswald | Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen |
| EP4580618A2 (en) * | 2022-08-30 | 2025-07-09 | Pannex Therapeutics Inc. | Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
| DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
| EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| WO1996026925A1 (en) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Arylthioacetamide derivatives |
| DE19738615A1 (de) * | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| DE19738616A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
| WO2000042026A1 (en) * | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| DE60037321D1 (de) | 1999-08-04 | 2008-01-17 | Icagen Inc | Benzanilide als öffner des kaliumkanals |
| CA2378243C (en) | 1999-08-04 | 2012-05-15 | Icagen, Inc. | Methods for treating or preventing pain and anxiety |
| HUP0303841A2 (hu) | 2001-02-20 | 2004-03-01 | Bristol-Myers Squibb Company | 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk |
| MXPA03007397A (es) * | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas. |
| US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| WO2002081728A2 (en) | 2001-04-06 | 2002-10-17 | Smithkline Beecham Corporation | Quinoline inhibitors of hyak1 and hyak3 kinases |
| AU2003272552A1 (en) | 2002-09-17 | 2004-04-08 | Pharmacia Corporation | Aromatic liver x-receptor modulators |
| WO2004058704A2 (en) | 2002-12-23 | 2004-07-15 | Icagen, Inc. | Quinazolinones as potassium channel modulators |
| EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
| CA2540978A1 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| BRPI0510598A (pt) | 2004-05-04 | 2007-11-20 | Pfizer | compostos de amida de aril ou heteroaril substituìdos |
| HUE032540T2 (en) * | 2004-06-24 | 2017-09-28 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| JP2008519814A (ja) | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
| US7812020B2 (en) | 2005-03-03 | 2010-10-12 | H. Lundbeck A/S | Substituted pyridine derivatives |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| ES2325558T3 (es) | 2005-07-20 | 2009-09-08 | Eli Lilly And Company | Derivados de piridina como inhibidores de dipeptidilpeptidasa. |
| WO2007030582A2 (en) | 2005-09-09 | 2007-03-15 | Bristol-Myers Squibb Company | Acyclic ikur inhibitors |
| WO2007057447A1 (en) | 2005-11-18 | 2007-05-24 | Neurosearch A/S | Novel quinazoline derivatives and their medical use |
| EP2057133B1 (en) | 2006-07-20 | 2014-08-20 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
| DE602007004638D1 (de) | 2006-07-20 | 2010-03-18 | Amgen Inc | Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin |
| US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| WO2008066900A1 (en) * | 2006-11-28 | 2008-06-05 | Valeant Pharmaceuticals International | 1,4 diamino bicyclic retigabine analogues as potassium channel modulators |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| AU2008285795A1 (en) | 2007-08-03 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands |
| EP2215065B1 (en) | 2007-10-19 | 2012-07-11 | Boehringer Ingelheim International GmbH | Ccr10 antagonists |
| WO2010102778A2 (de) * | 2009-03-10 | 2010-09-16 | Grünenthal GmbH | Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren |
| TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| TW201038565A (en) * | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier |
-
2010
- 2010-02-24 TW TW099105238A patent/TWI461197B/zh not_active IP Right Cessation
- 2010-03-10 US US12/720,864 patent/US20100234372A1/en not_active Abandoned
- 2010-03-11 NZ NZ595625A patent/NZ595625A/xx not_active IP Right Cessation
- 2010-03-11 RU RU2011141188/04A patent/RU2011141188A/ru not_active Application Discontinuation
- 2010-03-11 PE PE2011001567A patent/PE20120790A1/es not_active Application Discontinuation
- 2010-03-11 BR BRPI1008939A patent/BRPI1008939A2/pt not_active IP Right Cessation
- 2010-03-11 KR KR1020117023788A patent/KR20110132590A/ko not_active Withdrawn
- 2010-03-11 MX MX2011009369A patent/MX2011009369A/es active IP Right Grant
- 2010-03-11 EP EP10708726A patent/EP2406229A1/de not_active Withdrawn
- 2010-03-11 JP JP2011553352A patent/JP5727946B2/ja not_active Expired - Fee Related
- 2010-03-11 CA CA2755004A patent/CA2755004A1/en not_active Abandoned
- 2010-03-11 WO PCT/EP2010/001509 patent/WO2010102811A1/de not_active Ceased
- 2010-03-11 CN CN2010800112967A patent/CN102348692A/zh active Pending
- 2010-03-11 AU AU2010223513A patent/AU2010223513B2/en not_active Ceased
- 2010-03-12 AR ARP100100777A patent/AR075824A1/es not_active Application Discontinuation
-
2011
- 2011-08-24 CO CO11107978A patent/CO6410292A2/es not_active Application Discontinuation
- 2011-09-04 IL IL214945A patent/IL214945A0/en unknown
- 2011-09-08 CL CL2011002209A patent/CL2011002209A1/es unknown
- 2011-09-23 EC EC2011011348A patent/ECSP11011348A/es unknown
- 2011-10-11 ZA ZA2011/07444A patent/ZA201107444B/en unknown
-
2012
- 2012-06-15 US US13/523,955 patent/US8399673B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520249A5 (ja) | ||
| JP2012521966A5 (ja) | ||
| JP2018513107A5 (ja) | ||
| JP2009510044A5 (ja) | ||
| JP2014506321A5 (ja) | ||
| CA2676456A1 (en) | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof | |
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| NO20083562L (no) | Cannabinoidreseptormodulatorer | |
| JP2009533356A5 (ja) | ||
| JP2017528507A5 (ja) | ||
| JP2013507426A5 (ja) | ||
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| JP2010529118A5 (ja) | ||
| JP2009504622A5 (ja) | ||
| JP2015523321A5 (ja) | ||
| JP2015535270A5 (ja) | ||
| JP2016540749A5 (ja) | ||
| JP2016522254A5 (ja) | ||
| JP7167236B2 (ja) | せん妄の予防または治療剤 | |
| JP2016501219A5 (ja) | ||
| JP2013506003A5 (ja) | ||
| JP2009513604A5 (ja) | ||
| JP2014511897A5 (ja) | ||
| JP2013516475A5 (ja) |